share_log

Shattuck Labs | 8-K: Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

SEC announcement ·  Mar 1 05:23
Summary by Futu AI
Shattuck Labs, Inc., a clinical-stage biotechnology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on February 29, 2024. The company reported a net loss of $17.7 million for the quarter and $87.3 million for the full year. Despite the losses, Shattuck Labs highlighted several positive developments in its clinical trials, including promising data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine for treating Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia patients. The company also completed initial enrollment for Phase 1B dose-expansion cohorts and expects to provide updated data mid-year 2024. Additionally, Shattuck Labs entered into a strategic collaboration with Ono Pharmaceutical to develop novel bifunctional fusion proteins for autoimmune and inflammatory diseases and completed a $50 million offering of common stock and pre-funded warrants, extending its cash runway into 2026. The company's cash and cash equivalents and investments totaled $130.6 million as of December 31, 2023.
Shattuck Labs, Inc., a clinical-stage biotechnology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on February 29, 2024. The company reported a net loss of $17.7 million for the quarter and $87.3 million for the full year. Despite the losses, Shattuck Labs highlighted several positive developments in its clinical trials, including promising data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine for treating Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia patients. The company also completed initial enrollment for Phase 1B dose-expansion cohorts and expects to provide updated data mid-year 2024. Additionally, Shattuck Labs entered into a strategic collaboration with Ono Pharmaceutical to develop novel bifunctional fusion proteins for autoimmune and inflammatory diseases and completed a $50 million offering of common stock and pre-funded warrants, extending its cash runway into 2026. The company's cash and cash equivalents and investments totaled $130.6 million as of December 31, 2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.